Is Aprea Therapeutics Inc (APRE) undervalued? · $10.4M cap
Aprea Therapeutics Inc (APRE) is a biotechnology company listed on US.
This page asks whether Aprea Therapeutics Inc (APRE) looks cheap on cached numbers — not a DCF toy and not a buy alert.
Without a cached income statement, “undervalued APRE” is a slogan. Wait for the print.
APRE currently screens at market cap $10.4M. Cheap versus history or peers still needs a filing reason; a low multiple can be a value trap.
A new APRE 10-Q can flip this screen overnight. The SEC page is the source.
Not investment advice. Compare APRE to the stock page model before you treat a low multiple as a gift.
Not investment advice.